ReviewFrontiers in pharmacology2025
Targeting the AMP-activated protein kinase pathway: the active metabolites of botanical drugs represent potential strategies for treating metabolic-associated fatty liver disease.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Hyperforin as a Multifunctional Specialized Metabolite of Natural Origin for Chronic Diseases: From Molecular Mechanisms to Clinical Translation.Current issues in molecular biology · 2026Review
- Citrus Peel Xanthophylls Orchestrate Lipid-Glucose-Inflammation Axis Reprogramming in Cardiometabolic Syndrome: Integrative In Silico and In Vivo Evidence.Molecular nutrition & food research · 2026Article
- Cordycepin Ameliorates Constant Light-Induced Thermogenic Dysfunction in Brown Adipose Tissue by Activating SIRT1-Mediated Mitochondrial Homeostasis.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
AMP-activated protein kinase (AMPK) is capable of regulating cellular energy homeostasis and mitochondrial homeostasis. The activation of AMPK can ameliorate metabolic-associated fatty liver disease (MAFLD). An increasing number of studies have demonstrated that AMPK is a crucial enzyme in the regulation of glucose and lipid metabolism in the body, and numerous botanical drugs act as AMPK activators. This activation can alleviate glucose and lipid metabolism disorders, reduce oxidative stress, and serve as a pivotal therapeutic target for metabolic diseases. MAFLD represents the liver-related manifestation of metabolic syndrome. Currently, there are well - established antidiabetic drugs in clinical practice, yet they also entail side effects. A substantial number of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.